Molecular biomarkers of response to eribulin in patients with leiomyosarcoma

CONCLUSIONS: LMS has a complex genetic background, with multiple CNA and mutations affecting genes implicated in tumorigenesis. We identified several molecular changes with potential impact on survival of LMS patients when treated with eribulin.PMID:33795257 | DOI:10.1158/1078-0432.CCR-20-4315

Source: Clinical Cancer Research - April 2, 2021 Category: Cancer & Oncology Authors: Agnieszka Wozniak Bram Boeckx Elodie Modave Amy A Weaver Diether Lambrechts Bruce A Littlefield Patrick Sch öffski Source Type: research